Yahoo · Oct 30, 2026
Colgate Q3 Earnings Beat Estimates on Organic Sales & Pricing Gains
CL's Q3 earnings and sales beat estimates, fueled by organic growth, pricing gains and productivity efforts, prompting a higher 2026 profitability outlook.
NYSE · WRBY
Healthcare · Medical - Instruments & Supplies
$21.94
Down-$0.65 (-2.96%)
Updated Nov 4, 2026, 9:49 PM
SID Score
3.5/10
Composite research score
Smart Money
58/100
Neutral
Price performance · WRBY
1M range · 21 trading sessions · Daily adjusted prices
Prices through Nov 3, 2026
WRBY closed at $21.94 after 21 trading sessions, down 16.36% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 3, 2026 | $23.85 | $23.89 | $21.585 | $21.94 | 4.38M |
| Nov 2, 2026 | $24.59 | $25.94 | $23.76 | $23.86 | 3.77M |
| Oct 30, 2026 | $24.96 | $25.02 | $23.835 | $24.61 | 2.93M |
| Oct 29, 2026 | $24.76 | $25.27 | $24.42 | $24.59 | 2.6M |
| Oct 28, 2026 | $24.89 | $25.38 | $24.20 | $24.43 | 2.09M |
| Oct 27, 2026 | $25.44 | $25.57 | $24.46 | $25.07 | 2M |
| Oct 26, 2026 | $26.20 | $26.48 | $25.00 | $25.28 | 2.14M |
| Oct 23, 2026 | $25.43 | $26.13 | $25.005 | $25.91 | 1.91M |
| Oct 22, 2026 | $25.49 | $26.62 | $25.02 | $25.67 | 2.52M |
| Oct 21, 2026 | $25.63 | $26.02 | $24.88 | $25.63 | 1.75M |
| Oct 20, 2026 | $25.10 | $25.95 | $25.02 | $25.62 | 2.85M |
| Oct 19, 2026 | $23.84 | $25.18 | $23.60 | $24.99 | 4.4M |
| Oct 16, 2026 | $24.61 | $25.11 | $23.33 | $23.34 | 2.79M |
| Oct 15, 2026 | $25.29 | $25.545 | $24.395 | $24.59 | 4.09M |
| Oct 14, 2026 | $26.38 | $26.39 | $24.46 | $24.92 | 3.07M |
| Oct 13, 2026 | $26.13 | $27.00 | $25.76 | $26.52 | 2.84M |
| Oct 12, 2026 | $24.92 | $26.31 | $24.755 | $25.99 | 2.16M |
| Oct 9, 2026 | $24.92 | $25.34 | $24.57 | $25.30 | 1.54M |
| Oct 8, 2026 | $25.05 | $25.32 | $24.16 | $24.95 | 2.83M |
| Oct 7, 2026 | $25.98 | $26.41 | $25.29 | $25.31 | 1.73M |
| Oct 6, 2026 | $26.89 | $26.89 | $25.90 | $26.23 | 3.26M |
The latest Smart Investors Daily articles mentioning WRBY.
Company
Market Activity
Research & News
WRBY research
Company profile and research snapshot.
Warby Parker Inc is a mission-driven, lifestyle brand that operates at the intersection of design, technology, healthcare, and social enterprise. The company predominantly derives revenue from the sales of eyewear products, optical services, and accessories. The firm sells products and services through its stores, website, and mobile apps. Revenue generated from eyewear products includes the sales of prescription and non-prescription optical glasses and sunglasses, contact lenses, eyewear accessories, and expedited shipping charges.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 7, 2026 | UBS | Neutral | — |
| Aug 7, 2026 | Citizens | Market Outperform | — |
| Jun 29, 2026 | B of A Securities | Buy | — |
| May 8, 2026 | UBS | Neutral | — |
| May 7, 2026 | BTIG | Buy | — |
No generated briefing is available yet.
Yahoo · Oct 30, 2026
CL's Q3 earnings and sales beat estimates, fueled by organic growth, pricing gains and productivity efforts, prompting a higher 2026 profitability outlook.
Yahoo · Oct 20, 2026
Tecovas CEO David Lafitte joins host Elizabeth Gore to talk about how the "Warby Parker of cowboy boots" grew into a Western lifestyle brand with 50+ stores nationwide, and why “radical hospitality” is critical to the company’s success.
Yahoo · Oct 16, 2026
Samsung is bringing Gemini into Meta’s back yard
Yahoo · Oct 15, 2026
NEW YORK, October 15, 2026--Warby Parker Inc. (NYSE: WRBY) (the "Company"), a direct-to-consumer lifestyle brand focused on vision for all, today announced that its financial results for the third quarter ended September 30, 2026, will be released before market open on November 5, 2026.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.


The latest Smart Investors Daily articles mentioning WRBY.